A.U. Scherrer

Type de document

Articles (17)

Co-auteur

Date

Source

Mot-clé

cohorte (13) Swiss (12) Human beings (12) Treatment (11) Patients (11) Transmission (11) Patients (11) thérapie (10) Therapeutics (10) Drug resistance (9) Models (9) temps (durée) (8) Time (8) Use (8) Population (8) mutation (7) Methods (7) Infection (7) Methods (7) Mutation (7) résistance (7) virus (6) risque (6) art (6) infection (6) effet (6) adulte (6) Art (6) Art (6) Immunodeficiency (6)

Documents écrit par A.U. Scherrer (17) | parle de A.U. Scherrer (0)

Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.
C. Barceló et al.
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
C. Kadelka et al. (4 juin 2018)
Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
D. Kühnert et al.
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.
F. Bertels et al. (1 janv. 2018)
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.
T. Turk et al. (12 sept. 2017)
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.
M. Shilaih et al.
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs.
C.S. Oberle et al. (5 sept. 2016)
Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland.
M. Shilaih et al. (14 juin 2016)
Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds.
W.L. Yang et al. (2015)
Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
W.L. Yang et al. (2015)
Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.
W.L. Yang et al. (2015)
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
K.J. Metzner et al. (2013)
Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns.
J. Schüpbach et al. (2013)
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
A.U. Scherrer et al. (2012)
Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.
A.U. Scherrer et al. (2012)
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.
A.U. Scherrer et al. (2011)
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
A.U. Scherrer et al. (2011)